1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
China Shineway Pharmaceutical Group Limited

China Shineway Pharmaceutical Group Limited

CSWYF
China Shineway Pharmaceutical Group LimitedUS flagOther OTC
1.00
USD
- -
- -
758.42MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
Revenue per Share
2.64
2.7
2.48
2.41
2.32
3.15
3.47
3.51
4.27
5.23
5.98
5
4.15
Basic EPS, GAAP
0.83
0.85
0.8
0.71
0.55
0.62
0.64
0.39
0.74
0.96
1.28
1.11
1.26
Free Cash Flow per Basic Share
0.31
0.75
0.75
0.76
0.48
0.48
0.35
0.76
0.81
1.3
1.04
1.09
1.29
Dividend per Share
0.32
0.33
0.33
0.32
0.32
0.32
0.32
0.32
0.6
0.32
0.42
0.54
0.47
Book Value per Share
3.6
4.12
4.59
4.98
0.11
0.11
0.11
0.12
7.11
7.68
8.49
9.02
9.81
Tangible Book Value per Share
5.24
5.77
5.74
6.19
6.47
6.51
6.88
7.47
7.51
8.17
9.05
9.63
10.43
Basic Weighted Avg Shares
827
827
827
827
827
816
781
756
755
755
755
755
755
Sales/Revenue/Turnover
2,187
2,229
2,055
1,993
1,920
2,570
2,706
2,656
3,224
3,951
4,517
3,778
3,135
Operating Margin (%)
35.39
33.64
33.55
29.27
21.26
19.23
17.61
16.17
16.79
18.29
21.6
22.3
22.89
Depreciation Expense
102
148
166
195
199
202
205
208
182
186
60
69
71
Net Income, GAAP
684
705
658
589
452
506
503
295
557
723
970
840
950
Effective Tax Rate (%)
20.47
18.41
17.49
15.25
23.18
24.4
21.72
25.31
22.7
21.18
21.83
26.68
25.16
Profit Margin (%)
31.26
31.62
32.02
29.56
23.52
19.68
18.59
11.11
17.27
18.3
21.47
22.24
30.3
Working Capital
2,697
3,064
3,139
3,578
3,851
3,873
4,025
4,324
4,601
5,117
5,721
6,149
6,794
LT Debt
- -
- -
- -
- -
- -
- -
1
15
7
1
- -
8
1
Total Equity
4,430
4,893
5,296
5,627
5,821
5,766
5,777
5,794
5,901
6,383
7,035
7,467
8,062
Return on Invested Capital (%)
13.69
12.13
10.9
9.02
5.46
6.42
6.2
5.15
6.86
9.11
10.94
8.08
6.6
Return on Capital (%)
22.73
20.28
17.78
14.9
21.47
577.08
174.26
63.26
19.02
12.92
15.51
12.17
12.81
Return on Common Equity (%)
24.69
22.07
18.27
14.9
21.47
577.08
573.97
336.56
20.4
12.94
15.87
12.7
13.36

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.36%
6.87%
7.97%
Free Cash Flow
11.15%
14.09%
18.36%
Net Income, GAAP
8.87%
30.48%
13.08%
Sales/Revenue/Turnover
5.55%
4.98%
-17.01%
Total Cash Common Dividend
- -
17.57%
-12.96%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
4,517
2024
- -
- -
- -
- -
3,778
2025
- -
- -
- -
- -
3,135

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
1.28
2024
- -
- -
- -
- -
1.11
2025
- -
- -
- -
- -
1.26

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.42
2024
- -
- -
- -
- -
0.54
2025
- -
- -
- -
- -
0.47

Company Description

APIChat
CEO
Zhenjiang Li
Full Time Employees
3,220
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
No. 168 Shiluan Street Shijiazhuang People's Republic of China 051430
IPO Date
Feb 18, 2020
Website
shineway.com
Similar Companies
Sibannac, Inc. (SNNC)
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
Targeted Medical Pharma, Inc. (TRGM)
Chemesis International Inc. (CADMF)
Vita Life Sciences Limited (VLS.AX)
CanSino Biologics Inc. (688185.SS)
Business
China Shineway Pharmaceutical Group Limited, an investment holding company listed on the Hong Kong Stock Exchange under ticker 2877.HK (OTCPK: CSWYF), engages in the research, development, manufacture and trade of modern Chinese pharmaceutical products primarily in the People's Republic of China and Hong Kong. Founded in 2002 and headquartered in Shijiazhuang, Hebei Province, China, the company specializes in traditional Chinese medicines across various dosage forms, including injections such as Qing Kai Ling Injection, Shen Mai Injection, Shu Xue Ning Injection, Shuanghuanglian Injection, Dengzhanhua Su Injection and Yinzhi Huang Injection; soft capsules such as Wu Fu Xin Nao Qing Soft Capsule and Qing Kai Ling Soft Capsule; granules such as Chuanxiong Compressed Granules and Huamoyan Granule; traditional Chinese medicine formula granules; tablets such as Compound Licorice Tablet; oral liquids, pills and powders targeting therapeutic areas like respiratory system diseases, cardio-cerebrovascular conditions, nervous system disorders, digestive system diseases, orthopedics, pediatrics and body strengthening medications. The company operates through pharmaceuticals, healthcare products and research and development segments, with injections generating the majority of revenue, and maintains a diversified sales model involving direct sales to hospitals and clinics, partnerships with distributors and retail pharmacies, and exports contributing around 15% of total revenue. In recent developments, the group reported record revenue of RMB 4.2 billion for the year ended December 31, 2023, up 25% year-over-year, driven by strong sales of core products accounting for 70% of revenue; invested approximately RMB 600 million in R&D in 2024, a 12% increase, yielding new products like a novel herbal extract that boosted Q1 2024 sales by 15%; entered three strategic alliances in 2024 to expand research capabilities, including co-development of a new drug projected to generate over RMB 200 million in revenue by year-end; successfully won bids for eight key products in the National Procurement Alliance of Proprietary Chinese Medicine centralized procurements; and acquired 100% equity interest in Shineway-related entity as announced in its 2024 annual results on March 28, 2025.